APA (7th ed.) Citation

X, C., B, P., S, N., K, Y., JS, L., D, M., . . . A, G. (2022). Clinical Implications of Altered Drug Transporter Abundance/Function and PBPK Modeling in Specific Populations: An ITC Perspective. Clinical pharmacology and therapeutics, 112(3), 501. https://doi.org/10.1002/cpt.2643

Chicago Style (17th ed.) Citation

X, Chu, et al. "Clinical Implications of Altered Drug Transporter Abundance/Function and PBPK Modeling in Specific Populations: An ITC Perspective." Clinical Pharmacology and Therapeutics 112, no. 3 (2022): 501. https://doi.org/10.1002/cpt.2643.

MLA (9th ed.) Citation

X, Chu, et al. "Clinical Implications of Altered Drug Transporter Abundance/Function and PBPK Modeling in Specific Populations: An ITC Perspective." Clinical Pharmacology and Therapeutics, vol. 112, no. 3, 2022, p. 501, https://doi.org/10.1002/cpt.2643.